With the recent outbreak in Uganda, Mapp was contracted by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the US Department of Health and Human Services, to develop emergency doses of MBP134 to address this critical medical need.
Currently, there are no FDA-approved medical countermeasures available for SUDV.
KBI is playing an important role in supporting Mapp's efforts by providing expedited product development support including analytical and manufacturing contributions across multiple global sites.
In September 2022, public health authorities in the Republic of Uganda declared an outbreak of Ebola disease caused by SUDV. According to the World Health Organization, there were 142 confirmed cases and 55 deaths as of December 5, 2022.
Currently, there is no cure for Sudan ebolavirus virus disease, which has a fatality rate of around 50%.
While there is no widely available cure, promising therapeutic options such as MBP134 are in development. MBP134 is a two-antibody therapeutic candidate with demonstrated pan-ebolavirus efficacy in non-clinical studies.
Alternative therapeutic approaches are often restricted to a single member of the Ebolavirus genus.
In contrast, MBP134 confers unprecedented protection against antigenically diverse ebolaviruses at a single dosage.
KBI Biopharma, Inc., a JSR Life Sciences company, is a global contract development and manufacturing organization providing fully integrated, accelerated drug development and biologics manufacturing services and expertise to life science companies.
With each of its 500+ client partners, KBI works closely to personalize and rapidly accelerate drug development programs.
Built upon a foundation of world-class analytics capabilities and extensive scientific and technical expertise, KBI delivers robust process development and clinical and commercial cGMP manufacturing services for mammalian, microbial, and cell therapy programs.
Recognized for quality manufacturing, KBI helps partners advance drug candidates into the clinic and to the market.
KBI serves its global partners with eight locations in Europe and the USA.
Mapp Biopharmaceutical, Inc. (San Diego, CA) is a privately owned biotech company that develops novel antibody drugs to prevent and treat infectious diseases, focusing on unmet needs in global health and biodefense.
Circio unveils circVec proof-of-concept
GSK releases decade-long data on Shingrix efficacy
BiVictriX receives FDA Orphan Drug Designation for AML treatment candidate
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
GSK's meningitis vaccine candidate accepted for FDA review
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
ProAxsis secures GBP1.8m investment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients